A new treatment against an aggressive type of breast cancer authorized in France

Health Minister Olivier Veran has announced that a promising new treatment will be allowed from November 1

On Tuesday, the Minister of Health, Olivier Veran, announced that a promising new treatment against the aggressive form of breast cancer, known as “triple negative”, would be approved and available in France starting from 1He is November.

Against this cancer, “Finally there is a promising treatment produced by an American laboratory, called Trodelvy,” Olivier Veran affirmed during a questioning session at the association, in pink October, Breast Cancer Awareness Month.

France, the first European country to benefit from it

France was the first European country that was able to benefit a small number of patients while waiting for production to increase; I can confirm that it will be approved for early access and available in France from 1He is November 2021”, the Minister continued his talk about “good news”.

Trodelvy is an antibody treatment combined with chemotherapy, manufactured in the Gilead Laboratory. Triple negative breast cancer, a particularly aggressive form of the disease, is the least common, but accounts for about 15% of cases, or about 9,000 people each year.

At the beginning of September, the High Authority for Health (HAS) announced that patients with this cancer – which is not affected by current medicines – can exceptionally receive this new treatment that is not yet authorized. HAS granted Trodelvy early access for one year.

For its part, the Medicines Agency (ANSM) specified that Trodelvy was subject to an “Expedited Marketing Authorization Assessment (AMM) by the European Medicines Agency (EMA)”.

See also  Origin of Covid: China brings WHO back to the ropes

LEAVE A REPLY

Please enter your comment!
Please enter your name here